...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Vaccine >Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: The dynamics of PCV13 vaccine uptake
【24h】

Use of near-real-time medical claims data to generate timely vaccine coverage estimates in the US: The dynamics of PCV13 vaccine uptake

机译：在美国使用近实时医疗索赔数据生成及时的疫苗覆盖率估计：PCV13疫苗摄入的动态

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background: Vaccine coverage estimates lag by years in the US. Commercially available medical claims databases contain timely records of childhood vaccinations given in physician offices. We used such data to track the replacement of the 7-valent pneumococcal conjugate vaccine (PCV7) by PCV13, a new vaccine active against 6 additional serotypes, starting in March 2010. Methods: We developed an age cohort model to compute vaccination coverage over time. We used age-stratified, national projections of monthly PCV7 and PCV13 doses administered to children <5 years based on physicians' office claims, January 2008-May 2012. We assumed doses were given on schedule, and tracked cumulative numbers of doses given to aging monthly cohorts to estimate the percentage of children fully PCV13-immunized. To account for children uninsured or in the Vaccines for Children program, estimates were projected using National Immunization Survey coverage data. Results: PCV7 was phased out by June 2010. By March 2012, 82% of children 6-23 months were fully immunized with PCV13 and 42% of toddlers aged 15-59 months had received a catch-up PCV13 dose. For children aged 6-59 months, protective PCV13 coverage levels reached 33% and 56% by March 2011 and 2012, respectively, and were projected to reach 88% by March 2014. Our estimates for children aged 0-59 and 24-59 months are consistent with CDC's Immunization Information System sentinel sites data for 2011-2012. Conclusions: By using a simple analytic approach to compute vaccine coverage in aging cohorts from claims data, we show that PCV13 coverage rose rapidly as the PCV7 program was replaced. These estimates, validated against a CDC sentinel surveillance system in 8 states, should enable early documentation of the PCV13 impact on pneumococcal disease in the US. Moreover, they demonstrate the feasibility of tracking uptake patterns in near real-time even with simple summary counts of medical claims data
机译：背景：在美国，疫苗覆盖率估算值滞后数年。商业上可获得的医疗索赔数据库包含医师办公室提供的儿童接种疫苗的及时记录。我们使用这些数据跟踪从2010年3月开始用PCV13替代7价肺炎球菌结合疫苗（PCV7），这是一种对6种其他血清型具有活性的新疫苗。 。我们根据2008年1月至2012年5月根据医生办公室的要求，对年龄小于5岁的儿童使用了按年龄分层的每月PCV7和PCV13剂量的国家预测。每月队列估计完全接受PCV13免疫的儿童的百分比。为了说明没有保险的儿童或“儿童疫苗”计划中的儿童，使用国家免疫调查覆盖率数据预测了估计数。结果：PCV7于2010年6月被淘汰。到2012年3月，82％的6-23个月的儿童完全接受了PCV13的免疫接种，而42％的15-59个月的幼儿接受了PCV13的追赶剂量。对于6-59个月大的儿童，保护性PCV13的覆盖率到2011年3月和2012年分别达到33％和56％，预计到2014年3月将达到88％。我们对0-59个月和24-59个月的儿童的估计与CDC的2011-2012年免疫信息系统前哨站点数据一致。结论：通过使用简单的分析方法从索赔数据计算老龄人群的疫苗覆盖率，我们显示随着PCV7程序的替换，PCV13覆盖率迅速上升。这些估计值已在美国8个州的CDC前哨监视系统中进行了验证，应能早期记录PCV13对美国肺炎球菌疾病的影响。此外，他们证明了即使采用简单的医疗索赔数据汇总计数，也可以实时跟踪摄取模式的可行性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号